Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention

British Journal of Pharmacology

Volumn 117, Issue 7, 1996, Pages 1593-1599

  Pouna, Paul ^a   Bonoron Adèle, Simone ^b   Gouverneur, Gérard ^b   Tariosse, Liliane ^b   Besse, Pierre ^b   Robert, Jacques ^a,c,d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c INSTITUT BERGONIÉ   (France)

^d Dept Med Biochem and Molec Biol ^*  (France)

Author keywords

Anthracycline cardiotoxicity; Anthracycline liposomal formulations; Daunorubicin; Dexrazoxane; Doxorubicin; Epirubicin; Pirarubicin; Rat isolated perfused heart

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; PIRARUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACCUMULATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART PERFUSION; HEART PROTECTION; INTRAPERITONEAL DRUG ADMINISTRATION; ISOLATED HEART; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT;

EID: 0344309515     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15326.x     Document Type: Article

References (52)

1. BASSER, R.L. & GREEN, M.D. (1993). Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat. Rev., 19, 57-77.
2. BAURAIN, R., DEPREZ-DE CAMPENEERE, D. & TROUET, A. (1979). Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal. Biochem., 94, 112-116.
3. BU'LOCK, F.A., GABRIEL, H.M., OAKHILL, A., MOTT, M.G. & MARTIN, R.P. (1993). Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart. J., 70, 185-188.
4. DE JONG, J., GUÉRAND, W.S., SCHOOFS, P.R., BAST, A. & VAN DER VUGH, W.J.F. (1991). Simple and sensitive quantification of anthracyclines in atrial tissue using high-performance liquid chromatography and fluorescence detection. J. Chromatogr., 570, 209-216.
5. DE JONG, J., SCHOOFS, PR., SNABILIÉ, A.M., BAST, A. & VAN DER VIJGH, W.J.F. (1993). The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J. Pharmacol. Exp. Ther., 266, 1312-1320.
6. DE WILDT, D.J., DE JONG, Y., HILLEN, F.C., STEERENBERG, P.A. & VAN HOESEL, Q.G.C.M. (1985). Cardiovascular effects of doxorubicin-induced toxicity in the intact Lou/M Wsl rat and in isolated heart preparations. J. Pharmacol. Exp. Ther., 235, 234-240.
7. DEL TACCA, M., DANESI, R., SOLAINI, G., BERNARDINI, M.C. & BERTELLI, A. (1987). Effects of 4′-O-tetrahydropyanyl-doxorubicin on isolated perfused rat heart and cardiac mitochondrial cytochrome c oxidase activity. Anticancer Res., 7, 803-806.
8. FORSSEN, E.A. & ROSS, M.E. (1994). DaunoXome treatment of solid tumors: preclinical and clinical investigations. J. Liposome Res., 4, 481-512.
9. GABIZON, A.A. (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res., 52, 891-896.
10. GANZINA, F. (1983). 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat. Rev., 10, 1-22.
11. HASINOFF, B.B., DAVEY, J.P. & O'BRIEN, P.J. (1989). The adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper. Xenobiotica, 19, 231-241.
12. HASINOFF, B.B. & KALA, S.V. (1993). The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperaxinyl-1-yl)propane] and its hydrolysis product ADR-925. Agents Actions, 39, 72-81.
13. HASINOFF, B.B., REINDERS, F.X. & CLARK, V. (1990). The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-lyl)propane. Drug Metab. Disposit., 19, 74-80.
14. HÉRAIT, P., POUTIGNAT, N., MARTY, M. & BUGAT, R. (1992). Early assessment of a new anticancer drug analogue. Are the historical comparisons obsolete? The French experience with pirarubicin. Eur. J. Cancer, 28A, 1670-1676.
15. HERMAN, E.H. & FERRANS, V.J. (1986). Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol., 16, 102-106.
16. HERMAN, E.H. & FERRANS, V.J. (1993). Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother. Pharmacol., 32, 445-449.
17. HERMAN, E.H., FERRANS, V.J., YOUNG, R.S.K. & HAMLIN, R.L. (1988). Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res., 48, 6918-6925.
18. HIRANO, S., WAKAZONO, K., AGATA, N., IGUCHI, H. & TONE, H. (1994). Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp. Clin. Res., 20, 153-160.
19. IGUCHI, H., TONE, H., ISHIKUR, T., TAKEUCHI, T. & UMEZAWA, H. (1985). Pharmacokinetics and disposition of 4′-O-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother. Pharmacol., 15, 132-140.
20. ITO, H., MILLER, S.C., BILLIGHAM, M.E., AKIMOTO, H., TORTI, S.V., WADE, R., GAHLMANN, R., LYONS, G., KEDES, L. & TORTI, F.M. (1990). Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A., 87, 4275-4279.
21. 2+ transients observed in cardiac myocytes isolated from guinea-pig heart. Can. J. Physiol. Pharmacol., 72, 622-631.
22. JULICHER, R.H.M., STERRENBERG, L., BAST, A., RIKSEN, R.O.W.M., KOOMEN, J.M. & NOORDOEK, J. (1985). The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J. Pharm. Pharmacol., 38, 277-282.
23. LEANDRO, J., DYCK, J., POPPE, D., SHORE, R., AIRHART, C., GREENBERG, M., GILDAY, D., SMALLHORN, J. & BENSON, L. (1994). Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am. J. Cardiol., 74, 1152-1156.
24. LEE, V., RANDHAWA, A.K. & SINGAL, P.K. (1991). Adriamycin-induced myocardial dysfunction in vitro is mediated by free radical. Am. J. Physiol., 261, H989-H995.
25. LEGHA, S.S., BENJAMIN, R.S., MACKAT, B., YAP, H.Y., WALLACE, S., EWER, M., BLUMENSCHEIN, G.R. & FREIREICH, E.J. (1982). Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96, 133-139.
26. LEWIS, W., GALIZI, M. & PUSZKIN, S. (1983). Compartmentalization of adriamycin and daunorubicin in cultured chick cardiac myocytes. Circ. Res., 53, 352-362.
27. LIESMANN, J., BELT, R., HAAS, C. & HOOGSTRATEN, B. (1981). Phase I evaluation of ICRF-187 (NSC-169780) in patient with advanced malignancy. Cancer, 47, 1959-1962.
28. LIPSHULTZ, S.E., SANDERS, S.P., GOORIN, A.M., KRISCHER, J.P., SALLAN, S.E. & COLAN, S.D. (1994). Monitoring for anthracycline cardiotoxicity. Pediatrics., 93, 433-437.
29. LLESUY, S.F., MILEI, J., MOLINA, H., BOVERIS, A. & MILEI, S. (1985). Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4′-epiadriamycin in mice. Tumori, 71, 241-249.
30. LORELL, B.H., WEXLER, L.F., MOMOMURA, S., WEINBERG, E. & APSTEIN, C.S. (1986). The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ. Res., 58, 653-663.
31. MAEHARA, Y., SAKAGUCHI, Y., KUSUMOTO, T., KUSUMOTO, H. & SUGIMACHI, K. (1984). 4′-O-tetrahydropyranyladriamycin has greater antineoplastic activity than adriamycin in various human tumours in vitro. Anticancer Res., 9, 387-390.
32. MIMNAUGH, E.G., TRUSH, A. & GRAM, T.E. (1981). Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. Biochem. Pharmacol., 30, 2797-2804.
33. MONTI, E., PICCINNI, F., VILLANI, F. & FEVALLI, L. (1986). Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rats. Cancer Chemother. Pharmacol., 18, 289-291.
34. ONDRIAS, K., BORGOTTA, L., KIM, D.H. & EHRLICH, B.E. (1990). Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ. Res., 67, 1167-1174.
35. PELIKAN, P.C.D., WEISFELDT, M.L., JACOBUS, W.E., MICELI, M., BULKLEY, B.H. & GERSTENBLITH, G. (1986). Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in isolated, perfused rat heart. J. Cardiovasc. Pharmacol., 8, 1058-1066.
36. POUNA, P., BONORON-ADÈLE, S., GOUVERNEUR, G., TARIOSSE, L., BESSE, P. & ROBERT, J. (1995). Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother. Pharmacol., 35, 257-261.
37. PRESANT, C.A., SCOLARO, M., KENNEDY, P., BLAYNEY, D.W., FLANAGAN, B., LISAK, J. & PRESANT, J. (1993). Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet, 341, 1242-1243.
38. RABKIN, S.W. & SUNGA, P. (1987). The effect of doxorubicin (adriamycin) on cytoplasmic microtubule system in cardiac cells. J. Mol. Cell. Cardiol., 19, 1073-1083.
39. RHODEN, W., HASLETON, P. & BROOKS, N. (1993). Anthracyclines and the heart. Br. Heart. J., 70, 499-502.
40. SHIPP, N.G., DORR, R.T., ALBERTS, D.S., DAWSON, B.V. & HENDRIX, M. (1993). Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res., 53, 550-556.
41. SOLEM, L.E. & WALLACE, K.B. (1993). Selective activation of the sodium-independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria by doxorubicin. Toxicol. Appl. Pharmacol., 121, 50-57.
42. SPEYER, J.L., GREEN, M.D., KRAMER, E., REY, M., SANGER, J., WARD, C., DUBIN, N., FERRANS, V., STECY, P., ZELENIUCH-JACQUOTTE, A., WERNZ, J., FEIT, F., SLATER, W. BLUM, R. & MUGGIA, F. (1988). Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319, 745-752.
43. SPEYER, J.L., GREEN, M.D., ZELENIUS-JACQUOTTE, A., WERNZ, J.C., REY, M., SANGER, J., KRAMER, E., FERRANS, V., HOCHSTER, H., MEYERS, M., BLUM, R.H., FEIT, F., ATTUBATO, M., BURROWS, W. & MUGGIA, F.M. (1992). ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10, 117-127.
44. STEINHERZ, L.J., GRAHAM, T., HURWITZ, R., SONDHEIMER, H.M., SCHWARTZ, R.G., SHAFFER, E.M., SANDOR, G., BENSON, L. & WILLIAMS, R. (1992). Guidelines for cardiac monitoring of children during and after anthracycline therapy. Report of the cardiology committee of the children's cancer study group. Pediatrics, 89, 942-949.
45. TEMMA, K., AKERA, T., CHUGUN, A., KONDO, H., HAGANE, K. & HIRANO, S. (1993). Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur. J. Pharmacol., 234, 173-181.
46. THOMAS, C., VILE, G.F. & WINTERBOURN, C.C. (1993). The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem. Pharmacol., 45, 1967-1972.
47. UNVERFERTH, D.V., MAGORIEN, R.D., LEIER, C.V. & BALCERZAK, S.P. (1982). Doxorubicin cardiotoxicity. Cancer Treat. Rev., 9, 149-164.
48. VAN DER VIJGH, W.J.F., MAESSEN, P.A. & PINEDO, H.M. (1990). Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol., 26, 9-12.
49. VERHOEF, V., BELL, B. & FILPPI, J. (1988). Effect of the cardioprotective agent ADR-529 (ICRF-187) on the antitumor activity of doxorubicin. Proc. Am. Assoc. Cancer Res., 29, 273, (Abstract).
50. VILE, G.F. & WINTERBOURN, C.C. (1989). Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study. Cancer Chemother. Pharmacol., 24, 105-108.
51. VILLANI, F., GALIMBERTI, M., MONTI, E., PICCININI, F., LANZA, E., ROZZA, A., FAVALLI, L., POGGI, P. & ZUNINO, F. (1990). Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Rad. Res. Commun., 11, 145-151.
52. VOEST, E., VAN ACKER, S.A.B.E., VAN DER VIJGH, W.J.F., VAN ASBECK, B.S. & BAST, A. (1994). Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J. Mol. Cell. Cardiol., 26, 1179-1185.